Extension of corpus luteum lifespan and reduction of uterine secretion of prostaglandin F2 alpha of cows in response to recombinant interferon-tau

J Dairy Sci. 1995 Sep;78(9):1921-31. doi: 10.3168/jds.S0022-0302(95)76817-5.

Abstract

Two experiments tested the effect of recombinant ovine and bovine interferon-tau on corpus luteum lifespan, interestrous interval, and oxytocin-induced uterine secretion of prostaglandin F2 alpha. Cows received intrauterine injections of 100 micrograms of recombinant ovine interferon-tau plus 1.4 mg of BSA or of 1.5 mg of BSA alone in Experiment 1 and 200 micrograms of recombinant bovine interferon-tau plus 1.3 mg of BSA or 1.5 mg of BSA alone in Experiment 2. Twice daily injections (0700 and 1900 h) were split evenly between the uterine horns from d 14 to 24 of the experimental estrous cycle via an AI pipette in Experiment 1 and via intrauterine catheters in Experiment 2. On d 17, cows were injected with 100 IU of oxytocin, and plasma was collected for analysis of 13,14-dihydro-15-keto-prostaglandinF2 alpha. Recombinant ovine interferon-tau extended the lifespan of the corpus luteum (27.5 vs. 19.2 d) and interestrous interval (30.5 vs. 20.6 d) and abolished the oxytocin-induced increase in 13,14-dihydro-15-keto-prostaglandinF2 alpha, which peaked at 30 min for the BSA control group (210.8 pg/ml). Recombinant bovine interferon-tau also extended the lifespan of the corpus luteum (29.0 vs. 21.4 d) and interestrous interval (31.5 vs. 22.6 d) and abolished the oxytocin-induced increase in 13,14-dihydro-15-keto-prostaglandin F2 alpha, which peaked at 30 min for the BSA control group (205.6 pg/ml). In conclusion, recombinant ovine interferon-tau and recombinant bovine interferon-tau were effective antiluteolytic agents in cattle.

Publication types

  • Research Support, U.S. Gov't, Non-P.H.S.
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Animals
  • Body Temperature
  • Cattle / physiology*
  • Corpus Luteum / physiology*
  • Dinoprost / analogs & derivatives*
  • Dinoprost / metabolism
  • Female
  • Interferon Type I / administration & dosage
  • Interferon Type I / pharmacology*
  • Oxytocin / pharmacology
  • Pregnancy Proteins / administration & dosage
  • Pregnancy Proteins / pharmacology*
  • Progesterone / blood
  • Recombinant Proteins / pharmacology
  • Time Factors
  • Uterus / drug effects
  • Uterus / metabolism*

Substances

  • Interferon Type I
  • Pregnancy Proteins
  • Recombinant Proteins
  • interferon tau
  • 15-keto-13,14-dihydroprostaglandin F2alpha
  • Progesterone
  • Oxytocin
  • Dinoprost